DHI
D.R. Horton, Inc.
DHI has lower modeled downside risk, despite its lower overall score.
LCID
Lucid Group, Inc.
LCID has the edge over DHI overall, supported by stronger fundamentals and stronger modeled upside.
DHI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
DHI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
DHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.8x | $68.46 | -53% |
| Fair | 10x | $105 | -28% |
| Expensive | 13x | $132 | -8.8% |
| Current | 14x | $144 | — |
| Forward | 17x | $144 | — |
Historical ranges are pointers, not guarantees.
DHI's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
DHI Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Decline | |
| Stable | |
| Weakening | |
| Moderate | |
| Low |
Analysts expect DHI's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
DHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.71 | -14% |
| Q3 2026 | $10.14 | -12% |
DHI has the edge over LCID in the latest year-over-year earnings comparison.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
DHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.4B | -3.2% |
| Q2 2026 | $9.2B | 0% |
| Q1 2026 | $7.6B | -2.3% |
| Q4 2025 | $6.9B | -9.5% |
DHI's revenue has held roughly level: $9.4B last quarter, down 3.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -1.4 points |
| Q1 2026 | 11% | -2.3 points |
| Q4 2025 | 12% | -3 points |
| Q3 2025 | 12% | N/A |
| Q2 2025 | 15% | N/A |
| Q1 2025 | 14% | N/A |
| Q4 2024 | 15% | N/A |
DHI has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over DHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
DHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $397.3M | -43% |
| Q1 2026 | -$449.7M | +$20.8M |
| Q4 2025 | $826.6M | +31% |
DHI and LCID do not have enough comparable growth data to identify a winner.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
DHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -6M shares |
| 1 year | -7.2% | -21.9M shares |
DHI has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $600M |
| Q1 2026 | $930.3M |
| Q4 2025 | $669.7M |
| Q3 2025 | $700M |
| Q2 2025 | $1B |
| Q1 2025 | $1.3B |
| Q4 2024 | $1.1B |
DHI spent $2.9B buying back its own shares over the past year.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
DHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.4x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
DHI has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.0 | Neutral |
| Stochastic | 60.0 | Neutral |
DHI's weekly RSI is 49 (neutral) and its Stochastic is 60 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
DHI PE vs Consumer Cyclical Sector
| Metric | DHI | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 18x | 21% below |
| PE % | 96 | 47 | 49 pts above |
DHI is trading at 14x earnings, a 21% discount to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
DHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $142.6 | 1.3% above |
| 20 week MA | $145.2 | 0.5% below |
| 50 week MA | $148.3 | 2.6% below |
| 100 week MA | $144.7 | 0.2% below |
| 200 week MA | $140.9 | 2.5% above |
DHI has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
DHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.9 | $71.9 | +36% |
| 2021 | $71.9 | $104.9 | +46% |
| 2022 | $104.9 | $89.2 | -15% |
| 2023 | $89.2 | $152.0 | +70% |
| 2024 | $152.0 | $140.3 | -7.7% |
| 2025 | $140.3 | $146.3 | +4.3% |
| 2026 YTD | $146.3 | $144.5 | -1.3% |
DHI has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.